Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Filing Details

Accession Number:
Form Type:
Zero Holdings:
Publication Time:
2012-07-31 12:40:43
Reporting Period:
Filing Date:
Accepted Time:
2012-07-31 12:40:43
SEC Url:
Form 4 Filing
Cik Name Symbol Sector (SIC) IRS No
884629 Watson Pharmaceuticals Inc WPI Pharmaceutical Preparations (2834) 953872914
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1081534 G Fred Weiss C/o Fgw Associates
16450 Maddalena Place
Delray Beach FL 33446
Yes No No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock, Par Value $0.0033 Acquisiton 2012-07-30 30,000 $36.57 55,398 No 4 M Direct
Common Stock, Par Value $0.0033 Disposition 2012-07-30 30,000 $78.78 25,398 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock, Par Value $0.0033 Non-Qualified Options to Purchase Common Stock Disposition 2012-07-30 30,000 $0.00 30,000 $36.57
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
0 2007-05-17 2014-05-17 No 4 M Direct
  1. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $78.75 to $79.03, inclusive. The reporting person undertakes to provide to Watson Pharmaceuticals, Inc., any security holder of Watson Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (1) to this Form 4.
  2. Includes shares of restricted stock issued pursuant to the Fourth Amendment and Restatement of the 2001 Incentive Award Plan of Watson Pharmaceuticals, Inc.